Haruko Kunitomi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Haruko Kunitomi has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Eiji Sugihara
Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake, Japan
13 shared publications Nobuhiro Takahashi
13 shared publicationsNobuyuki Onishi
13 shared publicationsSayaka Yamaguchi-Iwai
13 shared publicationsTakatsune Shimizu
13 shared publicationsTatsuo Kuroda
13 shared publications
Latest Publications
- Open Access
- 12 February 2024
- Published by Springer Nature in Nature
- Vol. 626 (8001) , E21
Publisher Correction: Hypoblast from human pluripotent stem cells regulates epiblast development
- 12 February 2024
- Published by Springer Nature in Nature
- Vol. 626 (8001) , E21
Open AccessPublisher Correction: Hypoblast from human pluripotent stem cells regulates epiblast development
- Open Access
- 5 December 2023
- Published by Springer Nature in Nature
- Vol. 626 (7998) , 357-366
Hypoblast from human pluripotent stem cells regulates epiblast development
Recently, several studies using cultures of human embryos together with single-cell RNA-seq analyses have revealed differences between humans and mice, necessitating the study of human embryos1–8. Despite the importance of human embryology, ethical and legal restrictions have limited post-implantation-stage studies. Thus, recent efforts have focused on developing in vitro self-organizing models using human stem cells9–17. Here, we report genetic and non-genetic approaches to generate authentic hypoblast cells (naive hPSC-derived hypoblast-like cells (nHyCs))—known to give rise to one of the two extraembryonic tissues essential for embryonic development—from naive human pluripotent stem cells (hPSCs). Our nHyCs spontaneously assemble with naive hPSCs to form a three-dimensional bilaminar structure (bilaminoids) with a pro-amniotic-like cavity. In the presence of additional naive hPSC-derived analogues of the second extraembryonic tissue, the trophectoderm, the efficiency of bilaminoid formation increases from 20% to 40%, and the epiblast within the bilaminoids continues to develop in response to trophectoderm-secreted IL-6. Furthermore, we show that bilaminoids robustly recapitulate the patterning of the anterior–posterior axis and the formation of cells reflecting the pregastrula stage, the emergence of which can be shaped by genetically manipulating the DKK1/OTX2 hypoblast-like domain. We have therefore successfully modelled and identified the mechanisms by which the two extraembryonic tissues efficiently guide the stage-specific growth and progression of the epiblast as it establishes the post-implantation landmarks of human embryogenesis.
- 5 December 2023
- Published by Springer Nature in Nature
- Vol. 626 (7998) , 357-366
Open AccessHypoblast from human pluripotent stem cells regulates epiblast development
Recently, several studies using cultures of human embryos together with single-cell RNA-seq analyses have revealed differences between humans and mice, necessitating the study of human embryos1–8. Despite the importance of human embryology, ethical and legal restrictions have limited post-implantation-stage studies. Thus, recent efforts have focused on developing in vitro self-organizing models using human stem cells9–17. Here, we report genetic and non-genetic approaches to generate authentic hypoblast cells (naive hPSC-derived hypoblast-like cells (nHyCs))—known to give rise to one of the two extraembryonic tissues essential for embryonic development—from naive human pluripotent stem cells (hPSCs). Our nHyCs spontaneously assemble with naive hPSCs to form a three-dimensional bilaminar structure (bilaminoids) with a pro-amniotic-like cavity. In the presence of additional naive hPSC-derived analogues of the second extraembryonic tissue, the trophectoderm, the efficiency of bilaminoid formation increases from 20% to 40%, and the epiblast within the bilaminoids continues to develop in response to trophectoderm-secreted IL-6. Furthermore, we show that bilaminoids robustly recapitulate the patterning of the anterior–posterior axis and the formation of cells reflecting the pregastrula stage, the emergence of which can be shaped by genetically manipulating the DKK1/OTX2 hypoblast-like domain. We have therefore successfully modelled and identified the mechanisms by which the two extraembryonic tissues efficiently guide the stage-specific growth and progression of the epiblast as it establishes the post-implantation landmarks of human embryogenesis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Tumors comprise heterogeneous cell types including cancer stem cells (CSC), progenitor cells, and differentiated cells. Chemoresistance is a potential cause of relapse and a key characteristic of CSC, but the development of novel therapeutic approaches for targeting these cells has been limited. We previously established osteosarcoma-initiating (OSi) cells by introducing the gene for c-Myc into bone marrow stromal cells of Ink4a/Arf knockout mice. These OSi cells are composed of two distinct clones: highly tumorigenic cells (AX cells), similar to bipotent committed osteochondral progenitor cells, and tripotent cells of low tumorigenicity (AO cells), similar to mesenchymal stem cells. Here we show that depolymerization of the actin cytoskeleton induces terminal adipocyte differentiation and suppresses tumorigenesis in chemoresistant OSi cells. In contrast to AX cells, AO cells were highly resistant to conventional chemotherapeutic agents such as doxorubicin and were thus identified as chemoresistant cells. Inhibition of Rho-associated coiled-coil containing protein kinase (ROCK) elicited terminal adipocyte differentiation in chemoresistant AO cells through negative regulation of the transcriptional coactivator megakaryoblastic leukemia 1 associated with actin depolymerization. The clinically administered ROCK inhibitor fasudil significantly suppressed growth in vitro and tumorigenicity in vivo of chemoresistant AO cells as well as of OSi cells. Our findings thus suggest a new therapeutic strategy based on the induction of trans-terminal differentiation via modulation of actin cytoskeleton dynamics for therapy-resistant osteosarcoma stem cells.Significance:These findings suggest that induction of trans-terminal differentiation through regulation of actin dynamics is a potential novel therapeutic approach for targeting chemoresistant stem-like tumor cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Tumors comprise heterogeneous cell types including cancer stem cells (CSC), progenitor cells, and differentiated cells. Chemoresistance is a potential cause of relapse and a key characteristic of CSC, but the development of novel therapeutic approaches for targeting these cells has been limited. We previously established osteosarcoma-initiating (OSi) cells by introducing the gene for c-Myc into bone marrow stromal cells of Ink4a/Arf knockout mice. These OSi cells are composed of two distinct clones: highly tumorigenic cells (AX cells), similar to bipotent committed osteochondral progenitor cells, and tripotent cells of low tumorigenicity (AO cells), similar to mesenchymal stem cells. Here we show that depolymerization of the actin cytoskeleton induces terminal adipocyte differentiation and suppresses tumorigenesis in chemoresistant OSi cells. In contrast to AX cells, AO cells were highly resistant to conventional chemotherapeutic agents such as doxorubicin and were thus identified as chemoresistant cells. Inhibition of Rho-associated coiled-coil containing protein kinase (ROCK) elicited terminal adipocyte differentiation in chemoresistant AO cells through negative regulation of the transcriptional coactivator megakaryoblastic leukemia 1 associated with actin depolymerization. The clinically administered ROCK inhibitor fasudil significantly suppressed growth in vitro and tumorigenicity in vivo of chemoresistant AO cells as well as of OSi cells. Our findings thus suggest a new therapeutic strategy based on the induction of trans-terminal differentiation via modulation of actin cytoskeleton dynamics for therapy-resistant osteosarcoma stem cells.Significance:These findings suggest that induction of trans-terminal differentiation through regulation of actin dynamics is a potential novel therapeutic approach for targeting chemoresistant stem-like tumor cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10-19 from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Supplementary Fig. S10 Knockdown of either ROCK1 or ROCK2 alone induces terminal adipocyte differentiation and growth suppression of AO cells. Supplementary Fig. S11 Effect of chemical agents that induce depolymerization of the actin cytoskeleton on terminal adipocyte differentiation in AO cells. Supplementary Fig. S12 Immunohistochemical staining for MKL1 in an array of human osteosarcoma specimens. Supplementary Fig. S13 Effects of induction of a constitutively active mutant of MKL1 on the expression of MKL1 target genes in AO cells. Supplementary Fig. S14 Effects of fasudil treatment in mice injected with AO cells. Supplementary Fig. S15 Effect of fasudil treatment on terminal adipocyte differentiation in heterogeneous osteosarcoma cells. Supplementary Fig. S16 Effects of sequential treatment with doxorubicin and fasudil in heterogeneous osteosarcoma cells in vitro. Supplementary Fig. S17 Effects of sequential treatment with doxorubicin and fasudil in mice injected with heterogeneous osteosarcoma cells. Fig. S18 Osteogenic potential of AO and AX cells. Fig. S19 Effects of fasudil on the antiproliferative action of clinically administrated anticancer agents in AO cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10-19 from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Supplementary Fig. S10 Knockdown of either ROCK1 or ROCK2 alone induces terminal adipocyte differentiation and growth suppression of AO cells. Supplementary Fig. S11 Effect of chemical agents that induce depolymerization of the actin cytoskeleton on terminal adipocyte differentiation in AO cells. Supplementary Fig. S12 Immunohistochemical staining for MKL1 in an array of human osteosarcoma specimens. Supplementary Fig. S13 Effects of induction of a constitutively active mutant of MKL1 on the expression of MKL1 target genes in AO cells. Supplementary Fig. S14 Effects of fasudil treatment in mice injected with AO cells. Supplementary Fig. S15 Effect of fasudil treatment on terminal adipocyte differentiation in heterogeneous osteosarcoma cells. Supplementary Fig. S16 Effects of sequential treatment with doxorubicin and fasudil in heterogeneous osteosarcoma cells in vitro. Supplementary Fig. S17 Effects of sequential treatment with doxorubicin and fasudil in mice injected with heterogeneous osteosarcoma cells. Fig. S18 Osteogenic potential of AO and AX cells. Fig. S19 Effects of fasudil on the antiproliferative action of clinically administrated anticancer agents in AO cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-9 from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Supplementary Fig. S1 Differentiation potential of AO and AX cells. Supplementary Fig. S2 High Intrinsic efflux capacity contributes to the chemoresistance of AO cells. Fig. S3 Immunofluorescence microscopy of FABP4 and PLIN1 expression in heterogeneous osteosarcoma cells. Supplementary Fig. S4 Effect of doxorubicin on the expression of PPARG, a master regulator of adipogenesis, in human osteosarcoma cell lines. Supplementary Fig. S5 AO-like cells expressing PPARG are present in human recurrent osteosarcoma tissue but not in parosteal osteosarcoma tissue. Supplementary Fig. S6 Treatment with fasudil alone induces terminal adipocyte differentiation in AO cells but not in AX cells. Supplementary Fig. S7 Effect of fasudil treatment on terminal adipocyte differentiation in AO cells. Supplementary Fig. S8 Treatment with fasudil alone induces growth suppression in human osteosarcoma cell lines. Supplementary Fig. S9 Effects of doxorubicin or fasudil treatment in AOT cells which have lost their adipogenic potential in AO cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-9 from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Supplementary Fig. S1 Differentiation potential of AO and AX cells. Supplementary Fig. S2 High Intrinsic efflux capacity contributes to the chemoresistance of AO cells. Fig. S3 Immunofluorescence microscopy of FABP4 and PLIN1 expression in heterogeneous osteosarcoma cells. Supplementary Fig. S4 Effect of doxorubicin on the expression of PPARG, a master regulator of adipogenesis, in human osteosarcoma cell lines. Supplementary Fig. S5 AO-like cells expressing PPARG are present in human recurrent osteosarcoma tissue but not in parosteal osteosarcoma tissue. Supplementary Fig. S6 Treatment with fasudil alone induces terminal adipocyte differentiation in AO cells but not in AX cells. Supplementary Fig. S7 Effect of fasudil treatment on terminal adipocyte differentiation in AO cells. Supplementary Fig. S8 Treatment with fasudil alone induces growth suppression in human osteosarcoma cell lines. Supplementary Fig. S9 Effects of doxorubicin or fasudil treatment in AOT cells which have lost their adipogenic potential in AO cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods, Supplementary References from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Supplementary Materials and Methods, Supplementary References
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods, Supplementary References from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Supplementary Materials and Methods, Supplementary References
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
List of anticancer agents tested in the experiment shown in Supplementary Figure S19.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
List of anticancer agents tested in the experiment shown in Supplementary Figure S19.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Tumors comprise heterogeneous cell types including cancer stem cells (CSC), progenitor cells, and differentiated cells. Chemoresistance is a potential cause of relapse and a key characteristic of CSC, but the development of novel therapeutic approaches for targeting these cells has been limited. We previously established osteosarcoma-initiating (OSi) cells by introducing the gene for c-Myc into bone marrow stromal cells of Ink4a/Arf knockout mice. These OSi cells are composed of two distinct clones: highly tumorigenic cells (AX cells), similar to bipotent committed osteochondral progenitor cells, and tripotent cells of low tumorigenicity (AO cells), similar to mesenchymal stem cells. Here we show that depolymerization of the actin cytoskeleton induces terminal adipocyte differentiation and suppresses tumorigenesis in chemoresistant OSi cells. In contrast to AX cells, AO cells were highly resistant to conventional chemotherapeutic agents such as doxorubicin and were thus identified as chemoresistant cells. Inhibition of Rho-associated coiled-coil containing protein kinase (ROCK) elicited terminal adipocyte differentiation in chemoresistant AO cells through negative regulation of the transcriptional coactivator megakaryoblastic leukemia 1 associated with actin depolymerization. The clinically administered ROCK inhibitor fasudil significantly suppressed growth in vitro and tumorigenicity in vivo of chemoresistant AO cells as well as of OSi cells. Our findings thus suggest a new therapeutic strategy based on the induction of trans-terminal differentiation via modulation of actin cytoskeleton dynamics for therapy-resistant osteosarcoma stem cells.Significance:These findings suggest that induction of trans-terminal differentiation through regulation of actin dynamics is a potential novel therapeutic approach for targeting chemoresistant stem-like tumor cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Tumors comprise heterogeneous cell types including cancer stem cells (CSC), progenitor cells, and differentiated cells. Chemoresistance is a potential cause of relapse and a key characteristic of CSC, but the development of novel therapeutic approaches for targeting these cells has been limited. We previously established osteosarcoma-initiating (OSi) cells by introducing the gene for c-Myc into bone marrow stromal cells of Ink4a/Arf knockout mice. These OSi cells are composed of two distinct clones: highly tumorigenic cells (AX cells), similar to bipotent committed osteochondral progenitor cells, and tripotent cells of low tumorigenicity (AO cells), similar to mesenchymal stem cells. Here we show that depolymerization of the actin cytoskeleton induces terminal adipocyte differentiation and suppresses tumorigenesis in chemoresistant OSi cells. In contrast to AX cells, AO cells were highly resistant to conventional chemotherapeutic agents such as doxorubicin and were thus identified as chemoresistant cells. Inhibition of Rho-associated coiled-coil containing protein kinase (ROCK) elicited terminal adipocyte differentiation in chemoresistant AO cells through negative regulation of the transcriptional coactivator megakaryoblastic leukemia 1 associated with actin depolymerization. The clinically administered ROCK inhibitor fasudil significantly suppressed growth in vitro and tumorigenicity in vivo of chemoresistant AO cells as well as of OSi cells. Our findings thus suggest a new therapeutic strategy based on the induction of trans-terminal differentiation via modulation of actin cytoskeleton dynamics for therapy-resistant osteosarcoma stem cells.Significance:These findings suggest that induction of trans-terminal differentiation through regulation of actin dynamics is a potential novel therapeutic approach for targeting chemoresistant stem-like tumor cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods, Supplementary References from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Supplementary Materials and Methods, Supplementary References
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods, Supplementary References from ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells
Supplementary Materials and Methods, Supplementary References